Phase 1 × Recruiting × Myelodysplastic Syndromes × Clear all CELESTIAL-MDS
Phase 1 Recruiting
12 enrolled
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Phase 1 Recruiting
86 enrolled
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
Phase 1 Recruiting
42 enrolled
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
Phase 1 Recruiting
178 enrolled
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Phase 1 Recruiting
54 enrolled
AML-MDS 001
Phase 1 Recruiting
23 enrolled
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Phase 1 Recruiting
30 enrolled
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
Phase 1 Recruiting
18 enrolled
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory
Phase 1 Recruiting
54 enrolled
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Phase 1 Recruiting
120 enrolled
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
Phase 1 Recruiting
43 enrolled
Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
Phase 1 Recruiting
15 enrolled
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
Phase 1 Recruiting
20 enrolled
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
Phase 1 Recruiting
58 enrolled
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Phase 1 Recruiting
300 enrolled
Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
Phase 1 Recruiting
30 enrolled
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
Phase 1 Recruiting
24 enrolled
Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Phase 1 Recruiting
24 enrolled
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Phase 1 Recruiting
60 enrolled
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
Phase 1 Recruiting
48 enrolled
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
Phase 1 Recruiting
130 enrolled
Venetoclax AML
Phase 1 Recruiting
99 enrolled
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Phase 1 Recruiting
50 enrolled
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Phase 1 Recruiting
15 enrolled
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Phase 1 Recruiting
60 enrolled
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
Phase 1 Recruiting
36 enrolled
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
Phase 1 Recruiting
33 enrolled
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase 1 Recruiting
72 enrolled
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1 Recruiting
105 enrolled
IS-free Treg HaploHCT
Phase 1 Recruiting
30 enrolled
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
Phase 1 Recruiting
22 enrolled
Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 Recruiting
46 enrolled
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Phase 1 Recruiting
127 enrolled
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Phase 1 Recruiting
170 enrolled
A Study of GLB-001 in Patients With Myeloid Malignancies
Phase 1 Recruiting
108 enrolled
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Phase 1 Recruiting
291 enrolled 3 FDA
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
Phase 1 Recruiting
50 enrolled
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Phase 1 Recruiting
36 enrolled
A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies
Phase 1 Recruiting
168 enrolled
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
Phase 1 Recruiting
102 enrolled
A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies
Phase 1 Recruiting
100 enrolled
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 1 Recruiting
80 enrolled
CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
Phase 1 Recruiting
30 enrolled
BHARAT-1
Phase 1 Recruiting
80 enrolled
VICTORY
Phase 1 Recruiting
18 enrolled
CYCLE-1
Phase 1 Recruiting
27 enrolled